ArticleClinical and experimental medicine2025
Sustained AFP-L3 or DCP expression is associated with progression risk and inferior outcomes in unresectable hepatocellular carcinoma.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.Alimentary pharmacology & therapeutics · 2026Review
- Article
- Radioembolization (90Y) achieves higher response rates and reduces progression risk compared with DEB-TACE in hepatocellular carcinoma.Hepatology communications · 2026Article
- Development and temporal validation of 1-, 2-, and 3-year survival prediction models for hepatocellular carcinoma using the SEER database.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HCC biomarkers, Lens culinaris agglutinin fraction of AFP (AFP-L3) and des-gamma-carboxyprothrombin (DCP) with AFP, have been approved for surveillance in HCC but have not yet impacted disease management. In this prospective study, AFP, AFP-L3, and DCP were assessed as a non-invasive strategy to monitor residual disease and post-LDT changes in association with risk of disease progression. The biomarkers were measured at HCC diagnosis and following first cycle LDT. Response to LDT was evaluated using mRECIST. Time to event endpoints included time to advanced-stage disease progression, duration of overall complete response (oDoCR), and overall survival. The study included 182 patients with diverse biomarker profiling both at diagnosis and following first cycle LDT. Despite treatment, persistent biomarker expression was found in 36% (66/182) of patients with most (50/66) having elevations in AFP-L3 and/or DCP (AFP-L3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.